Indivior

Indivior

Indivior was established in 2014 when Reckitt Benckiser demerged its specialty pharmaceuticals division to focus on consumer health. The new entity took on a concentrated mission: treating opioid use disorder, a public-health crisis that gave its flagship product, Suboxone, a vast and durable market. CEO Mark Crossley, who took over in 2020, inherited a company already deep in litigation over generic competition and marketing practices, challenges that have shaped its defensive posture. The firm is incorporated in the United States and maintains its operational headquarters in Richmond, Virginia, with a secondary hub in Slough, United Kingdom. The company's strategy centers entirely on addiction medicine, a narrow therapeutic focus that makes it an outlier among mid-cap pharmaceutical firms. Its legacy revenue driver was Suboxone Film, a sublingual strip that delivered over $800 million in net revenue in its peak years, but that franchise has been under sustained pressure from generic manufacturers like Dr. Reddy's and Alvogen. The response has been a hard pivot to injectable buprenorphine: Sublocade, a monthly depot injection, and Perseris, a risperidone formulation for schizophrenia. Sublocade generated $630 million in net revenue in 2023 (per the firm's 2023 annual report), overtaking Suboxone Film and proving the injectable thesis. The geographic footprint is overwhelmingly North American, with the United States accounting for roughly 85% of net revenue. Indivior operates with a lean, litigation-heavy profile that reflects both its single-product origins and its ongoing settlement obligations. The company reached a $600 million resolution with the U.S. Department of Justice in 2020 over Suboxone marketing practices, a liability that continues to appear as a contingent consideration on its balance sheet. Crossley has since been reshaping the organization around a diversified injectable pipeline and an oral-overdose rescue medication, Opvee, acquired via a licensing deal. The team includes commercial and medical affairs professionals distributed between the Virginia headquarters and the UK research site. In November 2023, the firm announced it was evaluating a primary listing move from London to the United States to better align its equity story with its revenue base (per the firm's Q3 2023 trading update). The genuine structural differentiator of Indivior is its status as a public pharmaceutical company defined entirely by a single social pathology: the North American opioid epidemic. This makes its revenue stream uniquely vulnerable to public-health policy shifts and competitor generics in a way that broader pharma companies dilute through portfolio diversity. Its current architecture — a pure-play addiction-medicine firm — couples the end of a blockbuster era with a capital-market identity that few other listed entities share, creating a governance model where the CEO must navigate both patent cliffs and criminal settlements as standard operating conditions.